Newamsterdam Pharma Company N.v.NASDAQ: NAMS

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

· Issued by Newamsterdam Pharma Company N.v.
Watch Newamsterdam Pharma explain itNewAmsterdam Pharma Company N.V. (NAMS) Q2 2026 Earnings Call · Replay · Aug 5

-- Achieved primary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction (p